Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data

Oliver C. Stoss, Andreas Scheel, Iris Nagelmeier, Hans Ulrich Schildhaus, Thomas Henkel, Giuseppe Viale, Bharat Jasani, Michael Untch, Josef Rüschoff

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Recently the American Society of Clinical Oncology and the College of American Pathologists have updated their clinical practice guidelines for HER2 testing in breast cancer. In order to evaluate these new recommendations, we have re-assessed the HER2 status of 6018 breast cancer cases of the screening population for the HERceptin adjuvant (HERA) trial that were originally centrally tested by fluorescence in situ hybridization based on the FDA-released test guidelines. According to the most recent 2013 ASCO/CAP recommendations, 3380 (56.2%) cases were classified as HER2 positive compared with 3359 (55.8%) applying the HERA/FDA scheme and 3339 (55.5%) applying the 2007 ASCO/CAP guidelines. Twenty-one cases switched from negative (HERA/FDA scheme) to positive (2013 ASCO/CAP guidelines). This group is characterized by a mean HER2 gene copy number of ≥6.0, polysomy or co-amplification of CEP17 with an average CEP17 count of 5, and with HER2 receptor overexpression in 75% of cases. On the basis of the HER2 gene copy number alone, we observe 494 cases (8.2%) that are in the equivocal range. Most of these cases (>80%) were also nondecisive by immunohistochemistry (score 2+) irrespective of whether ratio was . The number of equivocal cases that would require HER2 reflex testing decreases to 113 (1.9%) if in addition to the HER2 gene copy number also the ratio of HER2 and CEP17 copy numbers is considered via dual-color in situ hybridization. The combination of applying the HER2 mean gene copy number as well as the HER2/CEP17 ratio to define equivocal test decisions by fluorescence in situ hybridization as proposed by the current ASCO/CAP guidelines appears to be a more optimum approach to adopt in order to avoid or minimize reporting of false negative results. Using the mean HER2 gene copy number alone for decision making results in a significant increase of equivocal cases.

Original languageEnglish
Pages (from-to)1528-1534
Number of pages7
JournalModern Pathology
Volume28
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

erbB-2 Genes
Gene Dosage
Fluorescence In Situ Hybridization
Guidelines
Breast Neoplasms
Early Detection of Cancer
Practice Guidelines
In Situ Hybridization
Reflex
Decision Making
Color
Immunohistochemistry
Trastuzumab
Population

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Stoss, O. C., Scheel, A., Nagelmeier, I., Schildhaus, H. U., Henkel, T., Viale, G., ... Rüschoff, J. (2015). Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data. Modern Pathology, 28(12), 1528-1534. https://doi.org/10.1038/modpathol.2015.112

Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data. / Stoss, Oliver C.; Scheel, Andreas; Nagelmeier, Iris; Schildhaus, Hans Ulrich; Henkel, Thomas; Viale, Giuseppe; Jasani, Bharat; Untch, Michael; Rüschoff, Josef.

In: Modern Pathology, Vol. 28, No. 12, 01.12.2015, p. 1528-1534.

Research output: Contribution to journalArticle

Stoss, OC, Scheel, A, Nagelmeier, I, Schildhaus, HU, Henkel, T, Viale, G, Jasani, B, Untch, M & Rüschoff, J 2015, 'Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data', Modern Pathology, vol. 28, no. 12, pp. 1528-1534. https://doi.org/10.1038/modpathol.2015.112
Stoss, Oliver C. ; Scheel, Andreas ; Nagelmeier, Iris ; Schildhaus, Hans Ulrich ; Henkel, Thomas ; Viale, Giuseppe ; Jasani, Bharat ; Untch, Michael ; Rüschoff, Josef. / Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data. In: Modern Pathology. 2015 ; Vol. 28, No. 12. pp. 1528-1534.
@article{515a612243534fe69a0fa14033281599,
title = "Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data",
abstract = "Recently the American Society of Clinical Oncology and the College of American Pathologists have updated their clinical practice guidelines for HER2 testing in breast cancer. In order to evaluate these new recommendations, we have re-assessed the HER2 status of 6018 breast cancer cases of the screening population for the HERceptin adjuvant (HERA) trial that were originally centrally tested by fluorescence in situ hybridization based on the FDA-released test guidelines. According to the most recent 2013 ASCO/CAP recommendations, 3380 (56.2{\%}) cases were classified as HER2 positive compared with 3359 (55.8{\%}) applying the HERA/FDA scheme and 3339 (55.5{\%}) applying the 2007 ASCO/CAP guidelines. Twenty-one cases switched from negative (HERA/FDA scheme) to positive (2013 ASCO/CAP guidelines). This group is characterized by a mean HER2 gene copy number of ≥6.0, polysomy or co-amplification of CEP17 with an average CEP17 count of 5, and with HER2 receptor overexpression in 75{\%} of cases. On the basis of the HER2 gene copy number alone, we observe 494 cases (8.2{\%}) that are in the equivocal range. Most of these cases (>80{\%}) were also nondecisive by immunohistochemistry (score 2+) irrespective of whether ratio was . The number of equivocal cases that would require HER2 reflex testing decreases to 113 (1.9{\%}) if in addition to the HER2 gene copy number also the ratio of HER2 and CEP17 copy numbers is considered via dual-color in situ hybridization. The combination of applying the HER2 mean gene copy number as well as the HER2/CEP17 ratio to define equivocal test decisions by fluorescence in situ hybridization as proposed by the current ASCO/CAP guidelines appears to be a more optimum approach to adopt in order to avoid or minimize reporting of false negative results. Using the mean HER2 gene copy number alone for decision making results in a significant increase of equivocal cases.",
author = "Stoss, {Oliver C.} and Andreas Scheel and Iris Nagelmeier and Schildhaus, {Hans Ulrich} and Thomas Henkel and Giuseppe Viale and Bharat Jasani and Michael Untch and Josef R{\"u}schoff",
year = "2015",
month = "12",
day = "1",
doi = "10.1038/modpathol.2015.112",
language = "English",
volume = "28",
pages = "1528--1534",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Impact of updated HER2 testing guidelines in breast cancer - Re-evaluation of HERA trial fluorescence in situ hybridization data

AU - Stoss, Oliver C.

AU - Scheel, Andreas

AU - Nagelmeier, Iris

AU - Schildhaus, Hans Ulrich

AU - Henkel, Thomas

AU - Viale, Giuseppe

AU - Jasani, Bharat

AU - Untch, Michael

AU - Rüschoff, Josef

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Recently the American Society of Clinical Oncology and the College of American Pathologists have updated their clinical practice guidelines for HER2 testing in breast cancer. In order to evaluate these new recommendations, we have re-assessed the HER2 status of 6018 breast cancer cases of the screening population for the HERceptin adjuvant (HERA) trial that were originally centrally tested by fluorescence in situ hybridization based on the FDA-released test guidelines. According to the most recent 2013 ASCO/CAP recommendations, 3380 (56.2%) cases were classified as HER2 positive compared with 3359 (55.8%) applying the HERA/FDA scheme and 3339 (55.5%) applying the 2007 ASCO/CAP guidelines. Twenty-one cases switched from negative (HERA/FDA scheme) to positive (2013 ASCO/CAP guidelines). This group is characterized by a mean HER2 gene copy number of ≥6.0, polysomy or co-amplification of CEP17 with an average CEP17 count of 5, and with HER2 receptor overexpression in 75% of cases. On the basis of the HER2 gene copy number alone, we observe 494 cases (8.2%) that are in the equivocal range. Most of these cases (>80%) were also nondecisive by immunohistochemistry (score 2+) irrespective of whether ratio was . The number of equivocal cases that would require HER2 reflex testing decreases to 113 (1.9%) if in addition to the HER2 gene copy number also the ratio of HER2 and CEP17 copy numbers is considered via dual-color in situ hybridization. The combination of applying the HER2 mean gene copy number as well as the HER2/CEP17 ratio to define equivocal test decisions by fluorescence in situ hybridization as proposed by the current ASCO/CAP guidelines appears to be a more optimum approach to adopt in order to avoid or minimize reporting of false negative results. Using the mean HER2 gene copy number alone for decision making results in a significant increase of equivocal cases.

AB - Recently the American Society of Clinical Oncology and the College of American Pathologists have updated their clinical practice guidelines for HER2 testing in breast cancer. In order to evaluate these new recommendations, we have re-assessed the HER2 status of 6018 breast cancer cases of the screening population for the HERceptin adjuvant (HERA) trial that were originally centrally tested by fluorescence in situ hybridization based on the FDA-released test guidelines. According to the most recent 2013 ASCO/CAP recommendations, 3380 (56.2%) cases were classified as HER2 positive compared with 3359 (55.8%) applying the HERA/FDA scheme and 3339 (55.5%) applying the 2007 ASCO/CAP guidelines. Twenty-one cases switched from negative (HERA/FDA scheme) to positive (2013 ASCO/CAP guidelines). This group is characterized by a mean HER2 gene copy number of ≥6.0, polysomy or co-amplification of CEP17 with an average CEP17 count of 5, and with HER2 receptor overexpression in 75% of cases. On the basis of the HER2 gene copy number alone, we observe 494 cases (8.2%) that are in the equivocal range. Most of these cases (>80%) were also nondecisive by immunohistochemistry (score 2+) irrespective of whether ratio was . The number of equivocal cases that would require HER2 reflex testing decreases to 113 (1.9%) if in addition to the HER2 gene copy number also the ratio of HER2 and CEP17 copy numbers is considered via dual-color in situ hybridization. The combination of applying the HER2 mean gene copy number as well as the HER2/CEP17 ratio to define equivocal test decisions by fluorescence in situ hybridization as proposed by the current ASCO/CAP guidelines appears to be a more optimum approach to adopt in order to avoid or minimize reporting of false negative results. Using the mean HER2 gene copy number alone for decision making results in a significant increase of equivocal cases.

UR - http://www.scopus.com/inward/record.url?scp=84949536462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949536462&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2015.112

DO - 10.1038/modpathol.2015.112

M3 - Article

C2 - 26403781

AN - SCOPUS:84949536462

VL - 28

SP - 1528

EP - 1534

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 12

ER -